RACHELLE DOODY to Amyloid beta-Peptides
This is a "connection" page, showing publications RACHELLE DOODY has written about Amyloid beta-Peptides.
Connection Strength
4.101
-
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease. JAMA Neurol. 2025 Jan 01; 82(1):19-29.
Score: 0.852
-
Thirty-Six-Month Amyloid Positron Emission Tomography Results Show Continued Reduction in Amyloid Burden with Subcutaneous Gantenerumab. J Prev Alzheimers Dis. 2021; 8(1):3-6.
Score: 0.645
-
What works and what does not work in Alzheimer's disease? From interventions on risk factors to anti-amyloid trials. J Neurochem. 2020 09; 155(2):120-136.
Score: 0.617
-
Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. N Engl J Med. 2014 04 10; 370(15):1460.
Score: 0.405
-
Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD). J Alzheimers Dis. 2025 Jan; 103(2):528-541.
Score: 0.212
-
At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact. J Prev Alzheimers Dis. 2024; 11(3):537-548.
Score: 0.199
-
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials. JAMA Neurol. 2022 11 01; 79(11):1113-1121.
Score: 0.183
-
The Future of Anti-Amyloid Trials. J Prev Alzheimers Dis. 2020; 7(3):146-151.
Score: 0.151
-
Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A?, tau, immunity and lipid processing. Nat Genet. 2019 03; 51(3):414-430.
Score: 0.142
-
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23; 370(4):311-21.
Score: 0.100
-
A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25; 369(4):341-50.
Score: 0.096
-
Prenatal hypoxia may aggravate the cognitive impairment and Alzheimer's disease neuropathology in APPSwe/PS1A246E transgenic mice. Neurobiol Aging. 2013 Mar; 34(3):663-78.
Score: 0.090
-
Long-term treatment with lithium alleviates memory deficits and reduces amyloid-? production in an aged Alzheimer's disease transgenic mouse model. J Alzheimers Dis. 2011; 24(4):739-49.
Score: 0.081
-
Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol. 2003 Dec; 60(12):1696-702.
Score: 0.049
-
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease. N Engl J Med. 2023 Nov 16; 389(20):1862-1876.
Score: 0.049
-
Development of a quantitative semi-mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q-ATN model). Alzheimers Dement. 2023 06; 19(6):2287-2297.
Score: 0.046
-
Therapeutic Targets for Alzheimer's Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report. J Prev Alzheimers Dis. 2022; 9(2):231-235.
Score: 0.043
-
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nat Med. 2021 Jul; 27(7):1187-1196.
Score: 0.042
-
Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force. J Prev Alzheimers Dis. 2021; 8(3):306-312.
Score: 0.040
-
Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report. J Prev Alzheimers Dis. 2019; 6(3):169-173.
Score: 0.035
-
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement. 2013 Jul; 9(4):438-44.
Score: 0.024